Targeted therapeutic mild hypercapnia after cardiac arrest.

We read the paper entitled “Clinical pathophysiology of hypoxic ischemic brain injury after cardiac arrest: a “two-hit” model” by Sekhon et al. published in Critical Care [1]. We agree that the clinical pathophysiologic impact of hypoxic ischemic brain injury after cardiac arrest (CA) is multi-factorial and complex. We are concerned, however, that the description of carbon dioxide management fails to address the potential therapeutic role of mild hypercapnia and identify current research directions underway to explicitly investigate targeted mild hypercapnia in the early post-resuscitation period.

Previously, from a large retrospective audit involving >16,000 patients from 125 Australian and New Zealand (ANZ) intensive care units (ICUs) following CA between 2000 and 2011, we found that, compared with normocapnia, hypercapnia was associated with a greater likelihood of discharge home among survivors [2]. More recently, the findings of our prospective phase II multi-centre randomised trial, the CCC trial, showed that targeting therapeutic mild hypercapnia (TTMH) (PaCO2 50-55 mmHg), compared to targeted normocapnia (TN) (PaCO2 35-45 mmHg) was feasible, appeared safe and resulted in attenuation of neuron specific enolase (NSE) release (a biomarker of brain injury) in resuscitated CA patients [3]. While at this stage only hypothesis generating, such findings suggest that mild hypercapnia could have neuro-protective properties during the immediate post-resuscitation phase. If proven to be beneficial, induction of hypercapnia would be an easy to apply intervention at minimal cost to most CA patients.

We agree that the current best evidence indicates that hypocapnia should be avoided, there is uncertainly whether normocapnia or TTMH is the optimal approach in the immediate post-resuscitation phase. There is sufficient uncertainty to justify a definitive trial to evaluate the potential benefit of mild hypercapnia. Indeed, we have now initiated the TAME Cardiac Arrest trial (Clinicaltrials.gov NCT03114033). This phase III multi-centre randomised controlled trial will determine whether TTMH, applied during the early post-resuscitation period, improves neurological outcome of resuscitated adult cardiac arrest patients admitted to the intensive care unit.

To the editor:

We acknowledge Eastwood et al. for their insightful comments to our narrative review entitled “Clinical pathophysiology of hypoxic ischemic brain injury after cardiac arrest: a “two hit” model”. They identify the importance of preventing secondary cerebral injury after cardiac arrest and the crucial role of arterial carbon dioxide induced modulation of cerebral blood flow and oxygen delivery. This effect occurs through the modulation of extracellular pH and is rendered less effective over time. Clearly, episodes of hypocapnia are associated with adverse outcome, stemming from cerebral vasoconstriction, reduced cerebral blood flow and oxygen delivery [1]. Conversely, in a large multicenter observational study, Schneider et. al demonstrated that patients with hypercapnia (PaCO2 > 45 mmHg on one blood gas in the first 24 hours) had higher rates of discharge home among survivors (OR 1.16, 95%CI: 1.03 – 1.32) [2].

Biologically, the phenomenon of “no reflow”, characterized by cerebral vasoconstriction, microvascular thrombi and subsequent cerebral oligemia early after resuscitation is well established [1]. It follows that mild hypercapnia to induce cerebral vasodilation may augment blood flow during this critical period and mitigate secondary injury. We commend Eastwood et al. for undertaking a foundational randomized control trial to investigate the role of mild hypercapnia (PaCO2 50-55 mmHg) after cardiac arrest compared with normocapnia (PaCO2 35-45 mmHg) (TAME trial; Clinicaltrials.gov NCT03114033) and eagerly await the results.

This trial will no doubt provide important insights into the management of post-resuscitative care of cardiac arrest patients. However, it should be noted that there is likely significant within-patient heterogeneity with respect to individual pathophysiology of hypoxic ischemic brain injury [1]. Randomized control trials of single physiological interventions in critical care may fail to account for these nuances. For example, two recent randomized trials of single physiological interventions aimed at mitigating secondary injury after cardiac arrest and traumatic brain injury, specifically targeted temperature management and transfusion thresholds, respectively, were negative [4, 5]. Hence our belief is that we should shift the paradigm to delineating the underlying individualized pathophysiology and establish personalized physiologic resuscitation targets following cardiac arrest. Our research group has recently demonstrated the ability to monitor cerebral autoregulation in real time after cardiac arrest to identify optimal and individualized mean arterial pressure [6]. We acknowledge that it remains unknown if individualized perfusion targets are associated with improved outcome after cardiac arrest. However, this strategy represents an intriguing shift towards personalized physiological resuscitation in the management of this catastrophic and complex disease.